Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2002
Business Overview: Cardinal Health is a leading provider of products and services to healthcare providers and manufacturers. Operations are conducted through four segments: Pharmaceutical Distribution and Provider Services, Medical-Surgical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services.
Key Financial Metrics
| Metric (in millions) | Fiscal 2002 | Fiscal 2001 |
|---|---|---|
| Operating Revenue | $44,394.3 | $38,660.1 |
| Total Revenue (incl. bulk deliveries) | $51,135.7 | $47,947.6 |
| Net Earnings | $1,056.2 | $857.4 |
| Diluted EPS | $2.30 | $1.88 |
| Operating Cash Flow | $983.9 | $871.7 |
| Total Assets | $16,438.0 | $14,642.4 |
| Long-term Obligations | $2,207.0 | $1,871.0 |
| Shareholders' Equity | $6,393.0 | $5,437.1 |
| Working Capital | $5,096.2 | $4,141.5 |
Note: Working Capital calculated as Total Current Assets ($11,906.6) minus Total Current Liabilities ($6,810.4).
Material Changes vs. Prior Period
- Revenue Growth: Total operating revenue increased 15% to $44.4 billion, driven by higher sales volume, pharmaceutical price increases (~5%), and new customer contracts. The Pharmaceutical Distribution segment accounted for 82% of operating revenue.
- Profitability: Net earnings rose 23% to $1.06 billion. Diluted earnings per share increased to $2.30 from $1.88.
- Margin Compression: Overall gross margin decreased to 9.1% from 9.3% due to a higher mix of lower-margin pharmaceutical distribution revenue and competitive pricing pressures.
- Special Charges: The company incurred $138.6 million in special charges (net of tax benefit: $87.1 million), primarily related to merger integration (Bindley consolidation) and restructuring. This reduced diluted EPS by $0.19.
- Accounting Changes: Adoption of SFAS No. 142 eliminated goodwill amortization, improving reported earnings. A change in revenue recognition for pharmacy automation equipment resulted in a cumulative effect charge of $70.1 million (net of tax).
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management anticipates continued growth through acquisitions and internal expansion. The company maintains a stable credit rating (A2/A/A) and believes it has adequate capital resources to fund operations and debt service. A new $500 million share repurchase program was authorized in August 2002.
Risks and Contingencies
- Customer Concentration: CVS Meridian Inc. accounted for 13% of operating revenue. CVS and Walgreens accounted for 80% of bulk deliveries (though bulk deliveries have negligible margin impact).
- Legal Proceedings:
- Latex Litigation: Approximately 380 pending lawsuits regarding latex sensitization. Potential liability estimated between $0 and $20 million net of insurance.
- Vitamin Litigation: Antitrust claims against vitamin manufacturers resulted in a $13.3 million gain in Q4 2002 (part of a $35.3 million total recovery).
- Environmental: Various claims (San Gabriel, A-1 Plainwell, Thermochem) are deemed immaterial to financial position.
- Regulatory: Significant exposure to changes in healthcare reimbursement, FDA regulations, and HIPAA compliance.
- Acquisition Risks: Integration of acquired businesses (e.g., Syncor, Magellan, BLP) poses operational and financial risks.
Unusual Items
The filing notes the dismissal of Arthur Andersen LLP as independent auditors on May 8, 2002, and the engagement of Ernst & Young LLP. No disagreements were reported regarding accounting principles.
Investor Verification Checklist
- Revenue Recognition: Verify the impact of the change in revenue recognition policy for pharmacy automation equipment (shift from delivery to installation) on future quarterly results.
- Special Charges: Monitor the completion of the Bindley distribution center consolidation and the associated remaining costs (estimated $75.9 million future merger-related costs).
- Customer Concentration: Assess the stability of the relationship with CVS (13% of revenue) and the impact of Kmart's Chapter 11 bankruptcy (approx. 5% of revenue, though credit exposure is limited via consignment).
- Legal Exposure: Track the resolution of latex litigation and the finality of the vitamin antitrust recovery.
- Acquisition Integration: Evaluate the progress and financial impact of the pending Syncor acquisition ($900 million value) and recent acquisitions (Magellan, BLP).